Daily News logo Newsletter logo   Search News    

Bend Research Signs License Agreement With Eli Lilly and Company

  Share This Story

BEND, Ore., Feb. 8, 2012 /PRNewswire/ -- Bend Research Inc. (www.bendresearch.com), a leading independent drug-formulation development and manufacturing company, announced today that it has entered into a licensing agreement with Eli Lilly and Company.

Under the terms of the agreement, Bend Research will make its proprietary spray-dried dispersion (SDD) technology available to Lilly. This technology, which improves the bioavailability of compounds with low aqueous solubility, has been applied successfully to hundreds of compounds at various stages of development, from preclinical studies to Phase III clinical trials. Lilly formulators and scientists will also have broad access to Bend Research's portfolio of other drug-delivery technologies.

In addition, as part of an already existing agreement with Lilly, Bend Research will continue to provide formulation, development, analytical, engineering and manufacturing services to Lilly to support its preclinical and clinical development programs.

"This expansion in our relationship with Lilly is a great milestone for us," said Rod Ray, Chief Executive Officer of Bend Research. "Our teams work well together and have a shared commitment to bring the best new medicines to caregivers and patients. We believe this collaboration will add significant value to Lilly's research efforts and help them advance their compounds more quickly and efficiently."

About Bend Research Inc.

For more than 35 years, Bend Research has worked with clients to create value by advancing new medicines that improve human health and to solve their most difficult scientific and technical problems. This success is based on the company's ability to develop, advance, and commercialize pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding.

Bend Research provides formulation and dosage-form support, assists in process development and optimization, manufactures clinical-trial quantities of drug candidates in its cGMP facilities, and advances promising drug candidates from conception through commercialization. Bend Research is a leader in novel formulations, including SDDs and hot-melt extrusions, and controlled-release, inhalation, and biotherapeutics technologies.

Bend Research has more than 240 employees based in four state-of-the-art facilities in Bend, Ore., USA. For more information about Bend Research, please contact Phoenix Ivers via email at Phoenix.Ivers@BendResearch.com, by phone at 541-382-4100 or 800-706-8655, or visit our website at www.bendresearch.com.

SOURCE Bend Research Inc.



 
Support Wikipedia

NeswBlaze top writers

Find more stories recommended by Stumbleupon.

newsletter logo

What's Hot?
1 .Breaking News: Cannes Film Festival Awards 2012 - 63
2 .Supermodel Bar Refaeli Adorns the Cover of the 2009 Sports Illustrated Swimsuit Issue on Newsstands Today! - 47
3 .Waterless 'Air Cooler PLUS' Beats Summer's Heat Without Making Your Home Muggy - 30
4 .Is It Coincidental We Have Another Missing Petite Blonde Coed, Mickey Shunick? - 22
5 .Round up of iPhone 5 Rumors From the Armenante Apple News Blog - 20
6 .Very Young Girls Movie Review: Sex, Class and Ho Daddies - 21
7 .These 10 Comfortable Walking Shoes Are a Step in the Right Direction - 14
8 .Give a Great Valedictorian Speech - Joey Asher - 12
9 .Ethiopia Celebrates Downfall of the Derg Day - 11
10 .Sandra Bullock's Naked Success - 9
Updated: 9:15 PDT     2177

NewsBlaze Editors

editors

NewsBlaze Writers

news writer images

Writers Wanted

Help NewsBlaze provide daily news, including top stories, Home and Garden, Technology, The Environment and more. NewsBlaze Writer

Follow NewsBlaze

NewsBlaze Social Media Logos NewsBlaze Facebook NewsBlaze LinkedIn NewsBlaze Twitter NewsBlaze YouTube NewsBlaze MySpace NewsBlaze Fan Page NewsBlaze StumbleUpon NewsBlaze Political Cartoons NewsBlaze Editorial Cartoons
NewsBlaze 
Copyright © 2004-2012 NewsBlaze LLC
Use of this website is subject to our Terms of Service and Privacy Policy  | DMCA Notice |         Press Room